A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.
Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash positio ...
Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...
Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...
Nir Giladi from TAU’s Faculty of Medical and Health Sciences and the Tel Aviv Sourasky Medical Center, as well as other researchers from TAU and the University of Haifa. The study was backed by the ...
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
Healthcare Asia on MSN1d
7MM Parkinson’s disease pipeline focuses on disease-modifying agentsThere are a total of 93 products in Phase I-III development for PD treatment. The Parkinson’s disease (PD) therapeutic ...
Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...
The test’s ability to distinguish ALS from similar conditions is particularly noteworthy. It could help physicians differentiate between ALS and conditions that mimic its symptoms, such as primary ...
According to recent research, astrocyte cell transplantation could revolutionize treatments for neurological disorders such ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback